Gyre Therapeutics (GYRE) Total Current Liabilities (2010 - 2026)

Gyre Therapeutics (GYRE) has reported Total Current Liabilities for 17 consecutive years, with $19.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Current Liabilities rose 4.2% year-over-year to $19.8 million; the TTM figure through Mar 2026 stood at $19.8 million (up 4.2% YoY), while the FY2025 annual figure was $18.3 million, down 6.3% from the prior year.
• Total Current Liabilities improved to $19.8 million in Q1 2026 per GYRE's latest filing, from $18.3 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $20.0 million in Q4 2023 and bottomed at $1.6 million in Q3 2022.
• Historically, Total Current Liabilities has averaged $13.1 million across 5 years, with a median of $15.6 million in 2024.
• Annual changes were most pronounced in 2022 — Total Current Liabilities sank 90.47% — and 2024, when it surged 725.35%.
• Gyre Therapeutics' Total Current Liabilities stood at $12.2 million in 2022, then surged by 63.76% to $20.0 million in 2023, then fell by 2.65% to $19.5 million in 2024, then declined by 6.3% to $18.3 million in 2025, then climbed by 8.21% to $19.8 million in 2026.
• Business Quant data shows GYRE's Total Current Liabilities at $19.8 million in Q1 2026, $18.3 million in Q4 2025, and $15.9 million in Q3 2025.